Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

The Boston-based biotech will use the new fundraise to develop its pipeline of drug candidates for conditions such as major ...

Investors and big pharma companies are waking up to the potential of techbio companies after years of avoidance, say experts ...

The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.

With innovative and flexible lab and manufacturing solutions being a critical success factor in drug development and delivery, SmartLabs, was delighted to announce the raise of $48 million series C ...

The big pharma company Sanofi has discontinued a phase 2 trial of U.S. partner Denali Therapeutics’ oditrasertib for the treatment of multiple sclerosis after the drug failed to perform. The K2 trial ...

As active pharmaceutical ingredients (APIs) and medicines become more complex and the demand for efficiency rises, drug ...